Fundamentals screen · refreshed after the Sep 28, 2026 close

Net-cash companies: Healthcare

Companies whose cash and investments exceed all debt by at least a quarter of their market value. Net cash is cash plus short-term investments minus debt, from the latest quarterly balance sheet.

CriteriaNet cash ≥ 25% of market capMarket cap ≥ $300MCommon stock95 stocks
#CompanyPriceNet cashMkt capRevenue YoYP/E
1EIKNEikon TherapeuticsHealthcare$7.91$531.2M$428.4M——
2ARVNArvinasHealthcare$7.51$567.6M$491.1M+1014.7%52.8×
3ARTVArtiva BiotherapeuticsHealthcare$7.05$349.4M$344.7M——
4BIOABioAge LabsHealthcare$7.18$318.7M$329.5M+1.6%—
5JANXJanux TherapeuticsHealthcare$16.58$970.9M$1.01B——
6BBOTBridgeBio Oncology TherapeuticsHealthcare$3.81$225.7M$305.5M——
7WVEWave Life SciencesHealthcare$3.67$490.6M$723.2M−73.9%—
8ASMBAssembly BiosciencesHealthcare$23.61$320.4M$480.7M+38.9%—
9CCCCC4 TherapeuticsHealthcare$3.12$253.7M$383.2M+2.8%—
10EVMNEvommuneHealthcare$8.39$200.4M$304.5M——
11PRTAProthenaHealthcare$8.72$288.2M$447.7M−77.1%—
12KLRAKailera TherapeuticsHealthcare$11.12$916.7M$1.44B——
13CRONCronos Group Inc. Common ShareHealthcare$3.41$797.0M$1.26B+59.5%18.0×
14GLUEMonte Rosa TherapeuticsHealthcare$11.71$621.1M$999.0M−61.3%—
15OLMAOlema PharmaceuticalsHealthcare$8.61$458.1M$753.4M——
16CABACabaletta BioHealthcare$2.00$205.1M$339.1M——
17ALLOAllogene TherapeuticsHealthcare$1.63$332.6M$563.2M——
18CTMXCytomX TherapeuticsHealthcare$2.69$330.3M$586.1M−92.4%—
19ALMSAlumisHealthcare$7.16$502.3M$926.8M−37.7%—
20PROKProKidneyHealthcare$1.61$181.6M$336.4M−32.1%—
21KURAKura OncologyHealthcare$10.61$509.2M$943.9M+36.5%—
22RLMDRelmada TherapeuticsHealthcare$3.79$217.7M$404.3M——
23VNDAVanda PharmaceuticalsHealthcare$5.17$166.9M$312.6M−3.9%—
24AVIRAtea PharmaceuticalsHealthcare$5.20$219.5M$417.1M——
25MPLTMapLight TherapeuticsHealthcare$10.45$304.7M$580.8M——
26ZURAZura Bio LimitedHealthcare$4.10$205.1M$392.9M——
27ENTAEnanta PharmaceuticalsHealthcare$12.62$189.5M$367.4M−21.6%—
28BNTCBenitec BiopharmaHealthcare$10.02$180.0M$349.5M——
29AURAAura BiosciencesHealthcare$6.15$323.8M$637.8M——
30ALTAltimmuneHealthcare$2.96$291.5M$575.8M−100.0%—
31JBIOJade BiosciencesHealthcare$14.35$461.2M$912.6M——
32AVTXAvalo TherapeuticsHealthcare$15.08$400.3M$808.7M——
33CTNMContineum TherapeuticsHealthcare$12.73$236.6M$478.9M——
34TECXTectonic TherapeuticHealthcare$23.51$226.9M$459.6M——
35PRLDPrelude Therapeutics IncorporatedHealthcare$3.91$151.8M$312.0M——
36SLDBSolid BiosciencesHealthcare$7.28$377.7M$780.6M——
37AKTSAktis OncologyHealthcare$19.35$517.3M$1.08B——
38LRMRLarimar TherapeuticsHealthcare$3.17$156.3M$329.3M——
39CAPRCapricor TherapeuticsHealthcare$8.71$237.9M$506.4M——
40ARCTArcturus Therapeutics HoldingsHealthcare$14.46$191.5M$411.0M−89.5%—
41MLTXMoonLake ImmunotherapeuticsHealthcare$11.56$437.5M$983.8M——
42ABEOAbeona TherapeuticsHealthcare$5.29$131.8M$302.5M+2745.0%—
43KARDKardiganHealthcare$14.78$597.6M$1.38B——
44VORVor BiopharmaHealthcare$18.31$466.1M$1.08B—1.7×
45DNAGinkgo Bioworks HoldingsHealthcare$10.46$302.2M$704.4M−48.5%—
46FDMT4D Molecular TherapeuticsHealthcare$14.56$341.7M$804.4M+25106.7%—
47DMRADamora TherapeuticsHealthcare$20.75$540.5M$1.28B——
48BEAMBeam TherapeuticsHealthcare$24.23$1.05B$2.50B−94.2%—
49CRMDCorMedixHealthcare$7.89$256.7M$615.0M+156.5%3.3×
50FLGTFulgent GeneticsHealthcare$22.36$256.6M$615.2M+4.4%—

Method & sources

Computed after each close from Massive / Polygon prices (split-adjusted), SEC filings, FINRA short-interest settlements and FMP earnings dates. Rows are rebuilt every session; a stock appears only when every criterion is met with current data. Full methodology

Informational screen, not a recommendation.

Net-cash companies · Healthcare (Sep 28) | Gainbot